Access the full text.
Sign up today, get DeepDyve free for 14 days.
B Gorski, C Cybulski, T Huzarski (2005)
Breast cancer predisposing alleles in PolandBreast Cancer Res Treat, 92
I Brozek, K Ochman, J Debniak (2008)
High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in PolandGynecol Oncol, 108
H Janiszewska, O Haus, A Lauda-Swieciak (2003)
Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujawy region of PolandClin Genet, 64
KE Malone, JR Daling, DR Doody (2006)
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women, ages 35 to 64�yearsCancer Res, 66
EM John, A Miron, G Gong (2007)
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groupsJAMA, 298
AP Sokolenko, NV Mitiushkina, KG Buslov (2006)
High frequency of BRCA1 5382insC mutation in Russian breast cancer patientsEur J Cancer, 42
M Ratajska, I Brozek, E Senkus-Konefka (2008)
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern PolandOncol Rep, 19
A Jasinska, WJ Krzyzosiak (2001)
Prevalence of BRCA1 founder mutations in western PolandHum Mutat, 17
M Perkowska, I Brozek, B Wysocka (2003)
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from north-eastern PolandHum Mutat, 21
AS Whittemore, G Gong, EM John (2004)
Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic WhitesCancer Epidemiol Biomarkers Prev, 13
DP Atchley, CT Albarracin, A Lopez (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancerJ Clin Oncol, 26
MC King, JH Marks, JB Mandell (2003)
Breast and ovarian cancer risk due to inherited mutation in BRCA1 and BRCA2Science, 302
B Gorski, T Byrski, T Huzarski (2000)
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancerAm J Hum Genet, 66
M Looij, B Wysocka, I Brozek (2000)
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern PolandHum Mutat, 15
I Brozek, C Cybulska, M Ratajska (2011)
Prevalence of the most frequent BRCA1 mutations in Polish populationJ Appl Genet, 52
PA James, R Doherty, M Harris (2006)
Optimal selection of individuals for BRCA mutation testing: a comparison of available methodsJ Clin Oncol, 24
HA Risch, JR McLaughlin, DE Cole (2006)
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in OntarioCan J Natl Cancer Inst, 98
JN Weitzel, VI Lagos, CA Cullinane (2007)
Limited family structure and BRCA gene mutation status in single cases of breast cancerJAMA, 297
D Huo, RT Senie, M Daly (2009)
Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, hispanic and other minority families in the United StatesJ Clin Oncol, 27
EM John (2010)
BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implicationsCurr Opin Obstet Gynecol, 22
AC Vargas, LD Silva, SR Lakhani (2010)
The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriersFam Cancer, 9
KA Metcalfe, A Poll, R Royer (2010)
Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish womenJ Clin Oncol, 28
E Grzybowska, H Zientek, A Jasinska (2000)
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancerHum Mutat, 16
It is estimated that about 5–10% of ovarian and 2–5% of all breast cancer patients are carriers of a germline BRCA1 or BRCA2 gene mutation. Most families with detected BRCA1 or BRCA2 gene mutation are qualified for molecular testing on the basis of family history of breast or ovarian cancers. The purpose of our study was to establish the frequency of positive family history of cancer in a series of Polish consecutive breast and ovarian cancer patients in two groups, with and without the BRCA1 gene mutations. We analysed the prevalence of four of the most common BRCA1 mutations: 5382insC (c.5266dupC), 300T>G (p.181T>G), 185delAG (c.68_69delAG) and 3819del5 (c.3700_3704del5). The patient group consisted of 1,845 consecutive female breast and 363 ovarian cancer cases. 19 out of 37 (51%) of BRCA1-positive ovarian cancer patients and 21 out of 55 (39%) BRCA1-positive breast cancer had negative family history of breast and/or ovarian cancer among first- and second-degree relatives. In ovarian cancer patients, negative family history was more frequent in those with 300T>G BRCA1 gene mutation than in 5382insC carriers. This finding indicates the necessity of searching for 300T>G mutation in families with a single diagnosis of ovarian cancer in family. The high frequency of mutations detected in breast cancer patients lacking obvious family history shows that breast cancer patients should be qualified for genetic testing on the basis of wide clinical and pathological criteria.
Familial Cancer – Springer Journals
Published: Mar 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.